SELECT PUBLICATIONS

Diaz-Rubio E, Schmoll HJ. The future development of bevacizumab in colorectal cancer. Oncology 2005;69(Suppl 3):34-45. Abstract

Giantonio BJ et al. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Presentation. Proc ASCO GI Cancers Symposium 2005;Abstract 169a.

Hecht JR et al. A randomized, double-blind, placebo-controlled, phase III study in patients (pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc ASCO 2005;Abstract 3.

Hochster HS et al. Results of the TREE-2 cohort: Safety, tolerability, and efficacy of bevacizumab added to three oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer. Proc ASCO GI Cancers Symposium 2006;Abstract 244.

Hochster HS et al. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial. Proc ASCO GI Cancers Symposium 2005a;Abstract 241.

Hochster HS et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/ fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 studies. Proc ASCO 2005b;Abstract 3515.

Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract

Jain RK et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40. Abstract

Jain RK. Antiangiogenic therapy for cancer: Current and emerging concepts. Oncology (Williston Park) 2005;19(4 Suppl 3):7-16. Abstract

Jain RK. Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62. Abstract

Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy. Nat Med 2001;7(9):987-9. No abstract available

Kabbinavar FF et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697-705. Abstract

Kabbinavar FF et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) to prolong progression-free survival in first-line colorectal cancer (CRC) in subjects who are not suitable candidates for first-line CPT-11. Proc ASCO 2004;Abstract 3516.

Kabbinavar F et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21(1):60-5. Abstract

Morgan B et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: Results from two phase I studies. J Clin Oncol 2003;21(21):3955-64. Abstract

Reddy GK. Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil/leucovorin regimen in dukes C colon cancer: Results from the X-ACT trial. Clin Colorectal Cancer 2004;4(2):87-8. No abstract available

Schleucher N et al. Phase I/II study of PTK787/ZK 222854 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Proc ASCO 2004;Abstract 3558.

Steward WP et al. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc ASCO 2004;Abstract 3556.

Twelves C et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352(26):2696-704. Abstract

Twelves C et al. Updated efficacy findings from the X-ACT phase III trial of capecitabine (X) vs bolus 5-FU/LV as adjuvant therapy for patients (pts) with Dukes’ C colon cancer. Proc ASCO 2005b;Abstract 3521.

Van Cutsem E et al. Oral capecitabine: Bridging the Atlantic divide in colon cancer treatment. Semin Oncol 2005;32(1):43-51. Abstract

Willett CG et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10(2):145-7. Abstract